PEG-MGF

Mechano Growth Factor is not an independent gene product but one of several peptides produced by alternative splicing of the insulin-like growth factor 1 (IGF-1) gene. The gene generates pro-IGF-1 isoforms (IGF-1Ea, IGF-1Eb, and IGF-1Ec) that share an identical mature IGF-1 region but differ in a C-terminal extension called the E-domain. In human skeletal muscle the mechanically responsive isoform is IGF-1Ec; in rodents the corresponding form is IGF-1Eb. A short insert shifts the reading frame in the E-domain-encoding exon, producing a unique C-terminal E-peptide whose isolated 24-residue fragment is what is synthesized and sold as MGF; PEG-MGF is that fragment conjugated to polyethylene glycol. A recurring framework in this literature is a two-phase model in which the E-peptide is associated with an early satellite-cell phase and the mature IGF-1 region with a later phase, examined through the signaling work described below.

Reports in this area describe more than one molecule under the single name. The widely used synthetic analog carries a histidine near the C-terminus (sequence ending …FEE-His-Lys) and is the form used in most peptide-chemistry work and by suppliers, whereas the native human E-domain ends in arginine (…FEE-Arg-Lys). A publicly resolvable PubChem entry corresponds to the native arginine free-acid peptide rather than the synthetic histidine analog, which is one reason the molecular formula and mass quoted for products in this class are inconsistent across sources. A further, separately engineered variant introduces C-terminal amidation and D-arginine substitutions intended to slow proteolysis (Mavrommatis et al., 2013; an earlier stabilizing strategy appears in Dłużniewska et al., 2005). Independent mass-spectrometric characterization of marketed material identified C-terminal amidated analogs rather than PEGylated species (Esposito et al., 2012), underscoring that products in this class are heterogeneous. CAS numbers circulated for the peptide could not be reconciled against primary registries and are treated here as unverified; the unmodified peptide is approximately 2.7 kDa.

The concept originated in stretch models of skeletal muscle. Yang, Alnaqeeb, Simpson and Goldspink (1996) cloned a second IGF-1 isoform from rabbit muscle subjected to stretch, using hybridization and RT-PCR methods, establishing the splice variant later termed MGF. McKoy et al. (1999) then used RNase-protection assays with a probe that distinguished the two spliced IGF-1 forms in rabbit muscle under stretch, stretch with electrical stimulation, and stimulation alone — the experimental basis for naming the transcript a 'mechano' growth factor, reflecting which mechanical conditions were examined. Cheema et al. (2005) extended the mechanical-signaling question to an in-vitro model of IGF-1 gene splicing during skeletal-muscle development.

A central line of work examined whether the isolated E-peptide acts through the IGF-1 receptor (IGF-1R) or through a separate pathway. Yang and Goldspink (2002) used C2C12 myoblasts transfected with MGF cDNA or exposed to the synthetic C-terminal peptide and assessed proliferation and myotube-formation endpoints, including a condition in which an IGF-1R-blocking antibody was present, to probe receptor dependence. Hill and Goldspink (2003) examined the temporal sequence of transcript expression relative to satellite-cell activation markers (M-cadherin, MyoD) in rodent muscle-damage models. Janssen et al. (2016) applied kinase-receptor-activation (KIRA) bioassays for the IGF-1 and insulin receptors, comparing full-length MGF, the isolated human E-peptide, and the stabilized analog, examining each for IGF-1R activation; the full-length construct retains the mature IGF-1 region whereas the isolated E-peptide does not. Kandalla et al. (2011) and Ates et al. (2007) studied the synthetic E-peptide in primary human muscle progenitor cells across donor ages and in normal, dystrophic, and ALS cultures, respectively.

The satellite-cell hypothesis is genuinely contested in the literature. Fornaro et al. (2014), in a multi-laboratory study, examined whether the MGF peptide altered proliferation of C2C12 cells and primary human skeletal-muscle myoblasts, whether it affected myoblast-to-myotube differentiation, and whether it activated ERK or Akt signaling in cardiac myocytes, comparing it against mature IGF-1 and full-length IGF-1Eb constructs. The authors framed their report as questioning whether the isolated peptide has a defined physiological role. Because much of the foundational mechanistic work originates from a single research group, this replication study is referenced here alongside the positive literature as part of an unresolved scientific debate rather than a settled conclusion.

Beyond skeletal muscle, the E-peptide has been examined across several preclinical model systems. Cardiac studies include a sheep myocardial-infarction model with echocardiographic assessment (Carpenter et al., 2008), a rat infarction model paired with cardiomyocyte cultures examining IGF-1R-independent signaling (Stavropoulou et al., 2009), and a mouse infarction model using pressure-volume analysis of the E-domain region (Mavrommatis et al., 2013). Neural model systems include a gerbil brain-ischemia model with organotypic hippocampal slices (Dłużniewska et al., 2005) and a mouse-brain neural-progenitor study of the splice variant (Mol Brain, 2017). Connective-tissue work includes a growth-plate chondrocyte model (Schlegel et al., 2013) and a rabbit bone-defect model in osteoblast research (Deng et al., 2011). In humans, evidence is limited to skeletal-muscle biopsy expression cohorts characterizing IGF-1 splice-variant transcripts (Hameed et al., 2003, 2004; Philippou et al., 2009); no interventional human studies of administered MGF or PEG-MGF were identified, so characterization of the molecule rests on these preclinical and expression datasets.